Fibrosis-Causing Agent for Lung Volume Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary emphysema, such as drug therapy and surgical methods, are ineffective in reducing lung capacity and often come with significant burdens and risks for patients, and existing fibrosis-causing agents do not adequately induce fibrosis to achieve lung volume reduction.
Innovation Solution
A fibrosis-causing agent composed of a fibrosis inducer and a fibrosis promoter, specifically combining polycations and platelet-rich plasma, is administered to induce fibrosis in lung tissues, reducing lung capacity and alleviating symptoms of pulmonary emphysema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing fibrosis-causing agents are used, then some fibrosis effect is achieved, but the fibrosis is insufficient to achieve desired lung capacity reduction
Solution Approach 1:
The patent combines a fibrosis inducer (polycation) and a fibrosis promoter (polyanion) into a single composition administered together. The polycation component induces fibrosis while the polyanion component promotes and enhances the fibrosis process, creating a synergistic effect that achieves sufficient lung capacity reduction where single agents failed
Solution Approach 2:
The invention uses a composite composition of polycation and polyanion materials. The specific combination of these two polymer types creates a more effective fibrosis-causing agent than either component alone, leveraging their complementary properties to achieve reliable lung volume reduction
2Ease of operation
If drug therapy and oxygen therapy are used, then symptoms are temporarily alleviated, but lung capacity is not reduced and treatment effectiveness is limited
Solution Approach 1:
Instead of trying to expand the lung or reduce resistance (conventional approach), this invention induces fibrosis to shrink the lung volume. By inverting the therapeutic goal from maintaining current lung function to actively reducing lung capacity, the treatment addresses the root cause of emphysema more directly
Solution Approach 2:
The invention fundamentally changes the therapeutic parameter from symptomatic management (bronchodilation) to structural modification (fibrosis-induced volume reduction). This parameter change transforms the treatment from temporary symptom relief to lasting anatomical correction
3Productivity
If surgical therapies like lung implantation or LVRS are used, then lung capacity may be reduced, but patients bear great burdens with poor prognosis and significant risks
Solution Approach 1:
The invention replaces mechanical surgical interventions (incisions, implants, resections) with a chemical/biological approach. By using a fibrosis-inducing composition administered through injection or inhalation, the treatment achieves lung volume reduction without the mechanical trauma, blood loss, and recovery burden associated with surgery
Solution Approach 2:
The treatment leverages the body's own fibrotic response mechanisms to achieve lung volume reduction. Rather than mechanically removing tissue, the composition triggers the patient's own tissues to undergo fibrosis and shrinkage, utilizing endogenous processes to accomplish what would otherwise require aggressive surgical intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of fibrosis inducers and promoters effectively causes fibrosis in lung tissues, reducing lung capacity and improving respiratory function by promoting tissue repair and resilience, offering a non-invasive alternative to existing treatments.
Implementation Method 1
a composition containing polycations and polyanions such that the ratio of X to Y is larger than about 1, where X denotes the product of the mass of polycations and the ratio of the electric charge per mass of polycations, and Y denotes the product of the mass of polyanions and the ratio of the electric charge per mass of polyanions
Data Source
AI summary
A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed.